Humana Price Target Raised to $125.00 at Oppenheimer (HUM)
Equities researchers at Oppenheimer lifted their price objective on shares of Humana (NYSE:HUM) from $105.00 to $125.00 in a research report issued on Thursday, American Banking News.com reports. The firm currently has an “outperform” rating on the stock. Oppenheimer’s price target would indicate a potential upside of 7.09% from the company’s current price.
Humana (NYSE:HUM) traded down 1.96% on Thursday, hitting $116.72. 2,055,351 shares of the company’s stock traded hands. Humana has a 52-week low of $77.98 and a 52-week high of $119.93. The stock has a 50-day moving average of $111.2 and a 200-day moving average of $103.4. The company has a market cap of $17.979 billion and a P/E ratio of 15.40.
Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $2.35 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.94 by $0.41. During the same quarter in the prior year, the company posted $2.69 earnings per share. On average, analysts predict that Humana will post $7.78 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which is scheduled for Friday, July 25th. Investors of record on Monday, June 30th will be given a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a yield of 0.96%. The ex-dividend date of this dividend is Thursday, June 26th. This is an increase from Humana’s previous quarterly dividend of $0.27.
Other equities research analysts have also recently issued reports about the stock. Analysts at FBR Capital Markets raised their price target on shares of Humana from $99.00 to $110.00 in a research note on Wednesday. They now have a “market perform” rating on the stock. Separately, analysts at Susquehanna raised their price target on shares of Humana from $101.00 to $110.00 in a research note on Thursday, April 10th. They now have a “neutral” rating on the stock. Finally, analysts at Cowen and Company raised their price target on shares of Humana from $110.00 to $120.00 in a research note on Tuesday, April 8th. Three investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and five have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $114.05.
Humana Inc (NYSE:HUM) is a health care company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.